Key result
Brain natriuretic peptide (BNP) and its N-terminal fragment (NT-pro-BNP) serve as accurate and independent biomarkers for the diagnosis, risk stratification, and prognosis of heart failure.
BNP and NT-pro-BNP are crucial biomarkers for diagnosing heart failure, assessing prognosis, and screening asymptomatic patients at risk for left ventricular dysfunction.
Brain natriuretic peptide (BNP) is a peptide hormone secreted by cardiomyocytes in response to atrial or ventricular wall stretch. It promotes a number of systemic effects, including vasodilatation, increase in urinary output and sodium excretion as well as inhibition of the sympathetic nervous system and the renin–angiotensin–aldosterone system. Plasma BNP levels have been reported to be elevated in patients with left ventricular hypertrophy, congestive heart failure, acute coronary syndromes, atrial fibrillation and impaired renal function. Moreover, elevated BNP levels have been shown to be a strong predictor of morbidity and mortality in patients with heart failure. Interestingly, it has also been found that the N-terminal peptide of BNP is slightly superior to BNP for predicting death or re-hospitalization for heart failure. Presumably, it is the longer half-life of NT-pro-BNP that may promote it as a more accurate index of ventricular stress and therefore a better predictor of prognosis.
No takes yet. Share an insight, caveat, or question.
Andreadis et al. (2015) conducted a review in Heart Failure. Brain Natriuretic Peptide (BNP) and NT-pro-BNP testing was evaluated. Brain natriuretic peptide (BNP) and its N-terminal fragment (NT-pro-BNP) serve as accurate and independent biomarkers for the diagnosis, risk stratification, and prognosis of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: